Efficacy of GLOW™ on Alleviating Symptoms of Inattention, Hyperactivity/Impulsivity, Depression and Sexual Dysfunction; A Preliminary Study

Abstract

Mental disorders are the leading cause of disability as measured by Years Lived with Disability; however, 40.5% of this burden is attributable to major depression [1]. Recent estimates of the prevalence of major depression indicate that 16.6% of adults in the US have been depressed at some point in their lifetime [2]. Symptoms of major depression include low mood, changes in appetite, sleep, or energy, and feelings of guilt or worthlessness [3]. Current medical treatments for major depression primarily involve synthetic antidepressants (e.g., monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, and selective serotonin reuptake inhibitors (SSRIs)) and psychological interventions (e.g., cognitive behavioral therapy, interpersonal therapy) [3,4]. However, psychological interventions may not be available for patients in need [4], and antidepressants may not effectively treat all depressed patients, with non-response rates of up to 50% [5]. Additionally, adverse effects, such as weight gain, insomnia, headache, anxiety and sexual dysfunction, occur frequently with antidepressant medication [6-8].